Building on the rationale that key glycolytic enzymes, such as HK2, LDHA, and PKM2, are central drivers of both tumor metabolism and the radioresistant TME, the following section focuses on therapeutic strategies directly targeting these molecules. Here, PKM is linked to neoplasm.